Nifty
Sensex
:
:
10763.40
35774.88
81.20 (0.76%)
317.72 (0.90%)

Pharmaceuticals & Drugs

Rating :
49/99

BSE: 540222 | NSE: LAURUSLABS

400.95
1.80 (0.45%)
19-Nov-2018 | 3:56PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  395.10
  •  404.35
  •  392.85
  •  399.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  55168
  •  221.20
  •  579.90
  •  330.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,223.41
  • 37.47
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 5,200.26
  • 0.38%
  • 2.83

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 33.40%
  • 4.94%
  • 11.08%
  • FII
  • DII
  • Others
  • 0.13%
  • 37.22%
  • 13.23%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 12.13
  • 4.97

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 15.21
  • 2.68

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 11.51
  • 7.71

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
588.28
538.61
9.22%
539.02
491.22
9.73%
560.24
0.00
0.00
478.93
0.00
0.00
Expenses
512.56
426.04
20.31%
458.46
394.71
16.15%
443.36
0.00
0.00
391.58
0.00
0.00
EBITDA
75.73
112.57
-32.73%
80.55
96.51
-16.54%
116.88
0.00
0.00
87.35
0.00
0.00
EBIDTM
12.87%
20.90%
14.94%
19.65%
20.86%
0.00%
18.24%
0.00%
Other Income
10.53
6.63
58.82%
2.59
7.54
-65.65%
5.08
0.00
0.00
9.94
0.00
0.00
Interest
24.64
19.52
26.23%
22.32
19.10
16.86%
23.26
0.00
0.00
17.76
0.00
0.00
Depreciation
39.82
30.08
32.38%
38.19
29.79
28.20%
34.61
0.00
0.00
30.98
0.00
0.00
PBT
21.79
69.60
-68.69%
22.62
55.17
-59.00%
64.09
0.00
0.00
48.55
0.00
0.00
Tax
5.58
20.84
-73.22%
6.07
16.27
-62.69%
19.01
0.00
0.00
13.68
0.00
0.00
PAT
16.21
48.76
-66.76%
16.56
38.91
-57.44%
45.08
0.00
0.00
34.87
0.00
0.00
PATM
2.76%
9.05%
3.07%
7.92%
8.05%
0.00%
7.28%
0.00%
EPS
1.52
4.60
-66.96%
1.56
3.68
-57.61%
4.25
0.00
0.00
3.29
0.00
0.00

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
2,166.47
2,056.17
1,904.65
1,777.58
1,326.59
1,159.72
Net Sales Growth
110.37%
7.96%
7.15%
34.00%
14.39%
 
Cost Of Goods Sold
1,146.46
1,056.02
989.29
1,000.15
821.27
720.43
Gross Profit
1,020.01
1,000.15
915.36
777.43
505.32
439.29
GP Margin
47.08%
48.64%
48.06%
43.74%
38.09%
37.88%
Total Expenditure
1,805.96
1,642.85
1,497.01
1,415.38
1,131.46
956.09
Power & Fuel Cost
-
94.21
66.27
57.95
49.86
35.03
% Of Sales
-
4.58%
3.48%
3.26%
3.76%
3.02%
Employee Cost
-
238.14
204.73
175.46
131.38
103.25
% Of Sales
-
11.58%
10.75%
9.87%
9.90%
8.90%
Manufacturing Exp.
-
150.78
139.47
106.97
80.61
47.96
% Of Sales
-
7.33%
7.32%
6.02%
6.08%
4.14%
General & Admin Exp.
-
73.17
65.42
49.09
28.39
27.30
% Of Sales
-
3.56%
3.43%
2.76%
2.14%
2.35%
Selling & Distn. Exp.
-
24.09
22.65
16.49
12.46
12.54
% Of Sales
-
1.17%
1.19%
0.93%
0.94%
1.08%
Miscellaneous Exp.
-
6.44
9.18
9.27
7.49
9.58
% Of Sales
-
0.31%
0.48%
0.52%
0.56%
0.83%
EBITDA
360.51
413.32
407.64
362.20
195.13
203.63
EBITDA Margin
16.64%
20.10%
21.40%
20.38%
14.71%
17.56%
Other Income
28.14
29.19
33.44
4.36
34.07
8.82
Interest
87.98
79.64
99.90
111.11
101.11
58.71
Depreciation
143.60
125.45
105.98
86.41
61.53
32.88
PBT
157.05
237.42
235.19
169.04
66.57
120.86
Tax
44.34
69.81
43.86
34.90
-1.55
23.64
Tax Rate
28.23%
29.40%
18.65%
20.65%
-2.33%
19.56%
PAT
112.72
167.61
191.33
134.14
68.12
97.22
PAT before Minority Interest
112.72
167.61
191.33
134.14
68.12
97.22
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
5.20%
8.15%
10.05%
7.55%
5.13%
8.38%
PAT Growth
28.57%
-12.40%
42.63%
96.92%
-29.93%
 
Unadjusted EPS
10.62
15.83
20.78
21.37
44.27
63.56

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
1,482.64
1,330.45
856.80
722.10
358.42
Share Capital
106.03
105.76
82.38
82.13
77.84
Total Reserves
1,370.75
1,218.84
771.47
637.03
277.22
Non-Current Liabilities
174.30
132.34
428.11
363.73
203.92
Secured Loans
141.66
124.56
353.61
303.68
188.17
Unsecured Loans
0.00
0.00
106.13
0.00
0.00
Long Term Provisions
20.84
14.59
6.77
5.13
3.93
Current Liabilities
1,306.89
1,120.75
883.75
802.49
710.87
Trade Payables
312.33
263.10
247.61
230.81
227.47
Other Current Liabilities
231.26
199.11
141.05
133.34
164.25
Short Term Borrowings
758.52
644.17
481.42
431.63
312.18
Short Term Provisions
4.78
14.37
13.66
6.70
6.97
Total Liabilities
2,963.83
2,583.54
2,168.66
1,888.32
1,273.21
Net Block
1,480.80
1,229.93
1,021.03
801.01
499.27
Gross Block
1,793.75
1,418.58
1,106.33
986.17
623.32
Accumulated Depreciation
312.95
188.65
85.30
185.16
124.04
Non Current Assets
1,716.23
1,443.71
1,165.92
1,024.41
696.70
Capital Work in Progress
163.18
143.26
69.60
109.67
116.10
Non Current Investment
3.40
3.40
7.04
7.45
0.00
Long Term Loans & Adv.
28.21
25.95
29.22
93.94
68.50
Other Non Current Assets
40.65
41.17
39.03
12.34
12.82
Current Assets
1,247.59
1,139.82
1,002.73
862.27
574.81
Current Investments
0.00
0.00
0.00
0.00
0.00
Inventories
584.78
509.05
487.09
475.50
328.10
Sundry Debtors
570.59
567.61
444.86
285.07
194.88
Cash & Bank
3.06
4.09
28.77
58.88
23.20
Other Current Assets
89.16
34.07
18.14
20.07
28.64
Short Term Loans & Adv.
58.63
25.01
23.86
22.75
19.80
Net Current Assets
-59.30
19.07
118.98
59.78
-136.06
Total Assets
2,963.82
2,583.53
2,168.65
1,888.32
1,273.21

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
342.49
331.99
181.97
-64.71
121.23
PBT
237.42
235.19
169.04
66.57
120.86
Adjustment
223.95
199.38
200.57
136.26
83.06
Changes in Working Capital
-56.96
-52.45
-154.37
-250.72
-59.27
Cash after chg. in Working capital
404.41
382.12
215.23
-47.89
144.65
Interest Paid
0.00
0.00
0.00
0.00
0.00
Tax Paid
-61.91
-50.13
-33.26
-16.82
-23.42
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-384.15
-288.67
-312.20
-396.95
-311.82
Net Fixed Assets
-394.43
-354.15
-76.75
-353.86
Net Investments
-1.22
-24.40
-7.01
-18.65
Others
11.50
89.88
-228.44
-24.44
Cash from Financing Activity
42.24
-53.61
103.32
486.08
203.03
Net Cash Inflow / Outflow
0.59
-10.30
-26.91
24.42
12.44
Opening Cash & Equivalents
2.42
12.81
39.53
15.11
2.67
Closing Cash & Equivalent
3.00
2.42
12.81
39.53
15.11

Financial Ratios

Standalone /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
139.28
125.25
499.30
419.61
189.14
ROA
6.04%
8.05%
6.61%
4.31%
7.64%
ROE
11.97%
18.12%
18.65%
14.47%
33.42%
ROCE
13.68%
16.52%
16.35%
13.74%
19.96%
Fixed Asset Turnover
1.29
1.53
1.73
1.66
1.87
Receivable days
100.40
95.66
73.56
65.47
61.02
Inventory Days
96.48
94.12
97.00
109.61
102.73
Payable days
61.13
59.14
58.52
69.29
86.77
Cash Conversion Cycle
135.75
130.64
112.05
105.79
76.98
Total Debt/Equity
0.66
0.64
1.20
1.14
1.54
Interest Cover
3.98
3.35
2.52
1.66
3.06

News Update:


  • Laurus Labs completes USFDA inspection at facility in Andhra Pradesh
    5th Nov 2018, 09:11 AM

    The manufacturing facility unit-6 is located at Atchutapuram in Visakhapatnam, Andhra Pradesh and has 42 reactors

    Read More
  • Laurus Labs - Quarterly Results
    1st Nov 2018, 17:24 PM

    Read More
  • Laurus Labs transfers ownership of HBV ANDA to CASI Pharmaceuticals
    24th Oct 2018, 09:49 AM

    Both parties are in discussions to allow Laurus to continue to manufacture and market TDF

    Read More
  • Laurus Labs gets approval from USFDA for Metformin Hydrochloride Tablets
    30th Aug 2018, 09:20 AM

    The Product and API will be commercialized from Company's Unit 2 located at APSEZ, Atchutapuram

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.